Healthcare Marketing Compliance: MENA and US Rules Side by Side

Compliance is the part of healthcare marketing that most teams treat as a gate at the end: write the campaign, send it to medical, legal and regulatory, wait, cut, resend. I have spent 15+ years on the marketing side of that gate at Pfizer, AbbVie and Johnson & Johnson and with hospitals, labs, pharmacies and digital health companies since. The teams that launch fastest are not the ones with the most permissive lawyers. They are the ones that treat compliance as a design input.

This guide puts the Middle East and the United States side by side, because most of the companies I work with operate in both or are moving from one to the other, and because the differences catch people out. It covers the rules that shape marketing decisions. It is not legal advice; work with qualified regulatory and legal counsel in each market.

1. Who regulates healthcare marketing

	United States	Middle East (Saudi Arabia, UAE, Egypt and the GCC)
Prescription medicines	FDA, through its Office of Prescription Drug Promotion; FTC for general advertising law	Saudi Food and Drug Authority (SFDA); UAE Ministry of Health and Prevention with the Dubai Health Authority and the Department of Health Abu Dhabi; the Egyptian Drug Authority (EDA); other national authorities in the GCC
Medical devices	FDA Center for Devices and Radiological Health; FTC	SFDA, UAE authorities, EDA and national device regulators
Healthcare providers and services	State medical boards, FTC, state consumer protection law	Ministries of health and emirate-level authorities, which license healthcare advertising content before publication
Industry self-regulation	PhRMA Code and AdvaMed Code (voluntary), Open Payments reporting (mandatory)	IFPMA Code of Practice applied through member companies and regional associations, plus company global codes
Personal data	HIPAA for covered entities and business associates; FTC Health Breach Notification Rule for many consumer health apps; state privacy laws	Saudi Personal Data Protection Law; UAE Personal Data Protection Law and the federal health data law; Egypt's Personal Data Protection Law (Law 151 of 2020)
Electronic marketing	CAN-SPAM for email, TCPA for calls and texts	Telecom and consumer protection rules, plus platform policies; consent expected for messaging channels

The first practical difference: in much of the Middle East, healthcare advertising is approved before publication by a health authority. In the US, prescription drug promotion is regulated mainly after the fact, through enforcement letters and litigation, while provider advertising is governed by general truth-in-advertising law and professional rules.

2. Prescription drug promotion

United States. Direct-to-consumer advertising of prescription medicines is allowed. Promotion must be consistent with the approved labeling, present fair balance between benefits and risks, and avoid off-label claims. Broadcast ads must include major risk information and point to full prescribing information. HCP promotion follows the same substantiation and fair-balance principles, and company interactions with HCPs are shaped by the Anti-Kickback Statute, the PhRMA Code and Open Payments, which makes payments to physicians and teaching hospitals public.

Middle East. Advertising prescription medicines to the public is prohibited. Promotion is to healthcare professionals only, with content approved by the regulator or governed by registration conditions, and the IFPMA Code's standards on accuracy, balance and substantiation apply to member companies. Disease awareness campaigns directed at the public are possible when they do not name a product and follow local approval rules. Over-the-counter medicines may be advertised to the public with prior approval of the content in most markets.

Design implications. A US brand entering the Gulf must separate its public and HCP content completely, build an HCP verification layer for digital channels, and budget time for pre-approval. A Gulf brand entering the US must learn fair balance and the mechanics of risk disclosure, and prepare for Open Payments reporting on every HCP engagement.

3. Medical device and digital health promotion

In both regions, device promotion is limited to the cleared or registered intended use, and every performance claim must be substantiated. The US adds the distinction between regulated software as a medical device and low-risk general wellness products, which decides whether a digital health app is marketed under FDA rules or general consumer law; the claims you make decide the category, so write the intended use statement before the marketing plan. In the Gulf, device registration with the SFDA or national authorities is a prerequisite for promotion and often for tender participation, and healthcare advertising permits may apply to the clinics that use the device as well as to the manufacturer.

For connected and AI-enabled products, both regions now expect cybersecurity and data governance to be documented, and the US FTC has pursued health apps for sharing user data with advertisers without clear consent. Treat data practices as part of the marketing claim set.

4. Healthcare provider advertising

United States. Hospitals and clinics advertise under general truth-in-advertising law and state medical board rules: no false or misleading claims, substantiated comparative claims, clear disclosure of material connections in testimonials and endorsements, and care with before-and-after imagery. Patient stories require HIPAA-compliant authorisation.

Middle East. Healthcare advertising by providers typically requires a permit from the health authority before publication, in Saudi Arabia, in Dubai and in Abu Dhabi, covering the content, the practitioners named and the platforms used. Rules commonly prohibit guaranteed results, discounts that encourage unnecessary treatment, and misleading before-and-after content, and they regulate the use of practitioner titles. Influencer and social media promotion of healthcare services is specifically covered in several markets.

Design implications. Build the permit timeline into the campaign calendar, keep a register of approved content and expiry dates, and give social media teams a pre-approved content pool rather than live creative freedom.

5. Data protection and digital channels

The questions a marketer must answer are the same in both regions: what personal data do we collect, on what legal basis, where is it stored, who processes it, how long do we keep it and how does a person exercise their rights?

United States. HIPAA governs protected health information held by providers, health plans and their business associates, including how it may be used for marketing; most pharma and consumer health marketing sits outside HIPAA and under the FTC and state privacy laws, which increasingly treat health data as sensitive. The FTC's Health Breach Notification Rule covers many health apps that HIPAA does not. CAN-SPAM governs commercial email; the TCPA governs calls and text messages and requires prior express consent for marketing texts.

Middle East. Saudi Arabia's Personal Data Protection Law, in force with enforcement from 2024, treats health data as sensitive, requires a lawful basis and clear consent for marketing, and restricts transfers outside the Kingdom. The UAE has a federal Personal Data Protection Law and a separate federal law on health data that restricts storing or transferring health information outside the country without approval. Egypt's Law 151 of 2020 requires consent and licensing for processing sensitive data. In practice, the Gulf rules push companies toward in-country hosting for patient data and explicit, documented consent for every digital channel, especially WhatsApp, which is a primary channel in the region.

Design implications. Capture consent per channel with wording, date and source; store health data in-region where the law requires; vet every marketing technology vendor for data location and sub-processors; and give patients and HCPs a working way to withdraw.

6. HCP interactions, medical education and KOLs

Both regions regulate what companies may give to and pay healthcare professionals.

United States: the Anti-Kickback Statute makes inducements to prescribe or purchase a serious offence; the PhRMA and AdvaMed codes set the norms for meals, educational items, speaker programs and consulting; Open Payments requires public reporting of transfers of value to physicians and teaching hospitals.
Middle East: the IFPMA Code and company global codes govern hospitality, speaker fees, sponsorship of congress attendance and grants, with local requirements on institutional approval for HCP participation and on the use of government-employed clinicians. Continuing medical education accreditation bodies, such as Kuwait's Institute for Medical Specialization in my rheumatology years at Janssen, set standards for accredited programs.

In both, the design rule is the same: fair market value contracts for genuine services, independent content for education, disclosed sponsorship, and documented approvals before the event. I describe the educational side in pharma medical education in the GCC.

7. The approval workflow that makes compliance a speed advantage

The companies that launch fastest in regulated markets share one operating practice: review happens at the module level, before campaigns, not at the campaign level, after creative.

Claims matrix. Every claim the brand may make, with its reference, approved wording and the markets in which it is permitted. Owned jointly by marketing and medical.
Modular content library. Approved units of content (a clinical summary, a dosing guide, a service description, a patient story with authorisation) that channels assemble rather than rewrite. Each module carries its approval reference, markets and expiry.
Reviewers in the room at the first draft. Medical, legal and regulatory see the message platform before copywriting starts. The review at the end becomes a check, not a rewrite.
Channel rules written down. What may appear on public pages, what requires HCP verification, which markets require a permit, and the consent wording per channel.
Monitoring and capture. Adverse events, product complaints and off-label questions routed from every digital channel, including social and messaging, with trained monitors.
A register and a calendar. Approvals, permits and expiry dates in one place, with renewal reminders.

With this in place, a new campaign is a recombination of approved parts plus a short review. Without it, every campaign starts from zero.

A compliance checklist for your next healthcare campaign

Which regulator approves or oversees this content in each market, and is a permit required before publication?
Is every claim in the claims matrix, with a reference and approved wording for this market?
Is public content separated from HCP content, with verification where required?
Do we present fair balance and risk information where the US requires it?
Is consent captured per channel, with wording, date and source, and honoured across systems?
Is health data stored and processed where the law requires, and have vendors been vetted?
Are HCP payments and hospitality within code, contracted at fair market value and reportable where required?
Are adverse event and complaint routes live for every channel, including messaging and social?
Who owns the approval register, and when does this content expire?

Frequently asked questions

Can pharmaceutical companies advertise prescription drugs to the public in the Middle East?

No. Across Saudi Arabia, the UAE, Egypt and the wider GCC, advertising prescription medicines to the public is prohibited. Promotion is directed to healthcare professionals, and disease awareness campaigns that do not name a product may be run with the appropriate approvals. Over-the-counter medicines may be advertised with prior content approval in most markets.

Do hospitals and clinics in the Gulf need approval to advertise?

In Saudi Arabia and the UAE, healthcare providers generally need a permit from the relevant health authority before publishing advertising, covering the content, the practitioners named and the platforms used, including social media and influencer promotion. Build the permit timeline into the campaign plan.

What data protection rules apply to healthcare marketing in Saudi Arabia and the UAE?

Saudi Arabia's Personal Data Protection Law treats health data as sensitive, requires a lawful basis and consent for marketing, and restricts cross-border transfers. The UAE's federal Personal Data Protection Law applies alongside a federal health data law that restricts storing or transferring health information outside the country. Both push toward in-country hosting and documented, per-channel consent.

Compliance is one of the six sectors of work on my healthcare marketing expert page, where it sits alongside pharma, medtech, digital health, providers and labs. For companies entering the Gulf, Middle East pharma market entry covers the commercial side of a regulatory-first launch. For the US digital health route, see launching a digital health app in the US.